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This study was conducted to determine the antimicrobial susceptibility patterns among common pathogens 
in the intensive care units (ICUs) of a university hospital in northwestern Iran. A retrospective study 
was done on laboratory records of patients with nosocomial infection who were admitted to five ICUs 
of Imam Reza Hospital during a 21-month period from March 2010 to January, 2012. A total number of 
556 isolates from 328 patients were evaluated. The most common sites of infections included respiratory 
(51.7%), urinary (24.8%), and blood (10.4%). The most frequently isolated microorganisms were 
Enterobacter aerogenes (50.6%) followed by Escherichia coli (16.7%) and Pseudomonas aeruginosa 
(7.5%). Staphylococcus aureus was the most frequent pathogen among gram-positives (39.7%). The 
rate of methicillin-resistant Staphylococcus aureus (MRSA) was 87.5%. Multidrug-resistant (MDR) 
gram-negative bacteria were documented in 25.8% of Acinetobacter, 20% of Klebsiella, and 16.6% 
of Pseudomonas. The most active antimicrobials were vancomycin (93.5%) followed by amikacin 
(71.5%) and gentamicin (46%). The overall antibiotic susceptibility was as follows: 36% ciprofloxacin, 
19% imipenem, 20% trimethoprim-sulfamethoxazole, 20.5% ceftazidime, and 12% ceftriaxone. Due to 
the high rate of antimicrobial resistance in the ICU setting, more surveillance and control of the use of 
antimicrobials is needed to combat infections.
Uniterms: Intensive care units/anti-infective agents/cross infection. Hospital University/Iran.
INTRODUCTION
Patients a d m i t t e d  t o  intensive care units (ICUs) 
are more vulnerable to various nosocomial infections 
because of their underlying illnesses and exposure to 
various invasive medical devices (Jatin, Mary, 2012; 
Archibald et al., 1997; Fridkin, 2001; Kollef, Fraser, 2001; 
Rhomberg et al., 2006).
Hospital infections affect approximately two million 
patients annually and lead to 90,000 deaths and a cost of 
$4.5 to $5.7 billion according to reports from the United 
States (Weinstein, 1998; Jarvis, 2001). They involve 
5-10% of ICU patients (CDC, 1992; Stone, Larson, Kawar, 
2002).
Antibiotics are the mainstay tools in the management 
of infections. Disappointingly, a number of studies have 
reported inappropriate uses of antimicrobials as well as 
the emergence of antibiotic resistance in most parts of 
the world (Tunger et al., 2009; Bergman et al., 2006). 
Today, the emergence of multidrug-resistant (MDR) gram-
negative and methicillin-resistant Staphylococcus aureus 
(MRSA) pathogens has become a major public health 
concern. Moreover, they negatively influence patients’ 
outcomes and increase the length of hospital stays and 
healthcare costs (Giske et al., 2008; De Kraker et al., 2011; 
Resch, Wilke, Fink, 2009; Mulvey, Simor, 2009).
Many studies have also showed that controlled use 
of antibiotics leads to improved microorganism sensitivity 
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to antimicrobial agents (Lee et al., 2010; Takesue et al., 
2010). The emergence of resistant pathogens and their 
negative impact on patient survival and healthcare costs 
need the evaluation of antimicrobial susceptibility in each 
health center and hospital in order to control infection. 
Therefore, this study assessed antimicrobial susceptibility 
patterns in the ICUs of the largest teaching hospital in 
northwestern Iran. To the best of the authors’ knowledge, 
this is the first report of bacterial resistance in ICUs at 
this location.
MATERIAL AND METHODS
Study Design and Setting
A retrospective study was done on laboratory 
records of the positive cultures patients with nosocomial 
infection who were admitted at the five ICUs of Imam 
Reza Hospital, a 500-bed tertiary care hospital affiliated 
to Tabriz University of Medical Sciences during a 
21-month period (March 2010 to January 2012). This 
study was approved in the ethic committee of the 
university.
Data and Sample Collection
For doing the study a questionnaire form was 
designed in order to record patients’ data included age, 
sex, file number, ward, culture results, site of infection, 
diagnostic species, and antibiogram test results. Prescribed 
drugs for ICU cultures were demonstrated using the 
hospital information system (HIS). All samples were taken 
in aseptic conditions. The sources of specimen included 
blood, urine, sputum, bronchial washing, wound, catheter, 
cerebrospinal fluid (CSF), tracheal, peritoneal, pleural, 
and synovial fluids.
Antimicrobial Susceptibility Testing
The Kirby-Bauer disk diffusion method was used to 
test antimicrobial susceptibility (in Mueller-Hinton agar 
medium, Merck, Germany) according to the guidelines of 
the National Committee for Clinical Laboratory Standards 
(NCCLS, 1997).
The performed antibiogram disks (Himedia 
laboratories, Mumbai, India) included vancomycin (V, 
30 mcg), ciprofloxacin (CIP, 5 mcg), clindamycin (CD, 
2 mcg), trimethoprim-sulfamethoxazole(SXT, 30 mcg), 
gentamicin (GM, 10 mcg), ofloxacin (OFX, 5 mcg), 
penicillin G (P, 10 mcg), oxacillin (OXA, 5 mcg), amikacin 
(AMK, 30 mcg), cefotaxime (CTX, 30 mcg), ceftazidime 
(CAZ, 30 mcg), ceftriaxone (CTR, 30 mcg), cefazolin (CZ, 
30mcg), chloramphenicol (CHL, 30 mcg), piperacillin 
(PIP, 100 mcg), imipenem (IPM, 10mcg), nitrofurantoin 
(FM, 50 mcg), ampicillin (AM, 10 mcg) and rifampin 
(RIF, 5 mcg).
Determination of Pattern of Antibiotic 
Prescriptions
A clinical pharmacist and two intensive care sub-
specialists evaluated the appropriateness of prescribed 
antibiotics based on result of each isolated cultures from 
ICU patients.
Patterns of antibiotic prescription based on culture 
results were divided into four groups: Group 1) Adherence 
with culture results, according to culture the drug is 
added or discontinued. Group 2) Not adherence with 
culture results as follows: 2-1) No change in medication; 
While, culture results showed resistance to antibiotics 
or following antibiotic therapy. We need to change the 
antibiotics but physician did not notice to culture results 
and antibiotics continued. 2-2) inappropriate changes in 
medication: the doctor noticed that you need to change the 
antibiotic, but changes were not accordance to protocols 
and appropriate drug that affect antibiotic therapy to 
improve patient has not chosen. 
Group 3) rational change without culture result 
guide: due to the lack of laboratory antibiogram test for 
all antibiotics, a rationale prescription of drugs by doctors 
was made.
Group 4) No judgment: Because there was no 
complete transparency in the medical record for patient, 
judgment in this case considered impossible by experts.
Antibiotics utilization rates in ICUs were determined 
by Defined Daily Dose (DDD) per 100 bed-days.
Data Analysis
Data were processed in SPSS 16. Results were 
shown as standard deviation fo r  quantitative variables 
and percentage for categorical variables.
RESULTS
A total number of 556 cultures isolated from 328 
patients who were admitted at the five ICUs of the 
hospital were included in the study. Of which, 55.5% 
(n=182) were males and 44.5% (n=146) were females. 
The mean (SD) forage of the patients was 54± 19.5 
years old. Data were collected from the five ICUs of 
the hospital as follows: 31.1% (n=102) from brain ICU, 
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22.6% (n=74) neurology ICU, 28.4% (n=93) lung ICU, 
16.5% (n=54) surgery ICU and 1.5% (n=5) from the 
general ICU. As shown, the brain ICU has the greatest 
number of patients.
The most common sites of infection included 
respiratory (40.6%), urine (24.8%) and blood (10.4%) 
followed by sputum (4.7%), CSF (4.7%), plural (3.9%), 
bronchial washing (3.6%), catheter (2.7%), abscess 
(2.2%), wound (2%), peritoneal (0.4%) and synovial 
(0.2%) specimen. The result of Gram staining showed 
that the majority of cultured samples (86.8%, n=483) were 
Gram-negative bacteria as well as 13.2% (n=74) were 
Gram-positive.
The most frequently isolated microorganisms were 
Enterobacter aerogenes (50.7%, n= 282) followed by 
Escherichia coli (16.7%) and Pseudomonas aeruginosa 
(7.5%). The prevalence of isolated microorganisms is 
given in Table I.
Among Gram-positives, Staphylococcus aureus 
was the most frequently isolated pathogen (39.7%, n=29) 
followed by Staphylococcus epidermidis. Susceptibility 
rates of Gram-positive and Gram-negative microorganisms 
are shown in Table II and III respectively. Based on these 
findings, rate of methicillin resistance Staphylococcus 
aureus (MRSA) was 87.5%. However, all cases of 
Staphylococcus aureus and 90% of Staphylococcus 
epidermidis were sensitive vancomycin.
In the present study, multidrug resistant (MDR) 
Gram-negative bacilli were documented in 25.8% 
of Acinetobacter, 20% of Klebsiella and 16.6% of 
Pseudomonas. The susceptibility rate of Enterobacter, 
Escherichia coli and Pseudomonas aeruginosa to imipenem 
were 16.4%, 16.6% and 46% respectively. These rates 
for ciprofloxacin were 34.5%, 43.5%, and 56.5% and 
to amikacin were 64.5%, 88%, and 62.5% respectively. 
Regarding gentamicin, these susceptibility rates were 
42.5%, 53.7%, and 38.5% respectively.
Overall susceptibility rates of the microorganisms 
isolated from the ICUs are also shown in table IV. The 
most active antimicrobials were vancomycin (93.5%) 
followed by amikacin (71.5%) and gentamicin (46%). 
The overall susceptibility of isolated microorganisms 
to regular important antibiotics was as follows: 36% for 
ciprofloxacin, 19% for imipenem, 20% for trimethoprim-
sulfamethoxazole, 20,5%for ceftazidime, and 12% for 
ceftriaxone.
The most Staphylococcus strains were observed in 
lung and blood samples (31% and 17.2% respectively).
Enterobacter and E.coli were the most commonly 
isolated pathogens from urine samples (37.7% and 36.2% 
respectively as well as the most frequently isolated 
microorganisms from lung samples were Enterobacter 
(52.7%) followed by Pseudomonas aeruginosa (10.2%) 
and Acinetobacter (9.1%). Entrobacter aerogenes was 
the most common strain in all samples. Entrobacter 
aerogenes and E.coli was the most commonly detected 
microorganisms in most ICUs.
Pattern of antibiotic prescription showed that only 
22.5% of prescriptions were in accordance with culture 
results and 34.5% were not adherence with culture results. 
Moreover, in 38% of prescriptions logical changes were 
made without culture result guide. In 5%, no judgment 
could be made.
The rate of antibiotics utilization included as follows: 
ciprofloxacin (8.7mg per 100 bed-days), meropenem (5.4 mg 
per 100 bed-days), cefepime (4.2 mg per 100 bed-days), 
imipenem (3.1 mg per 100 bed-days), ceftazidime (1.9 mg 
per 100 bed-days), amikacin (0.9 mg per 100 bed-days), 
gentamicin (0.8 mg per 100 bed-days), ceftriaxone (8 mg 
per 100 bed-days), vancomycin (4.3 mg per 100 bed-days), 
piperacillin-tazobactam (2.8 mg per 100 bed-days).
DISCUSSION
To the best of the authors’ knowledge, this is the first 
report from the ICUs of the largest teaching hospital in 
northwestern Iran. The result of this study highlighted the 
important key role of rational prescription of antibiotics. 
This matter becomes more important when it concerns the 
emergence of antimicrobial resistance produced by gram-
negative bacilli and MRSA strains (Giske et al., 2008; De 









Enterobacter aerogenes, n (%) 282 (50.7)
Esherichia coli, n (%) 93 (16.7)
Pseudomonas aeruginosa, n (%) 42 (7.6)
Acintobacter spp. n (%) 31 (5.6)
Unclassified Gram-negative bacteria, n (%) 25 (4.5)
Klebsiella spp. n (%) 5 (0.9)
Enterobacter + E.coli, n (%) 5 (0.9)









Staphylococcu saureus, n (%) 29 (5.2)
Staphylococcus epidermidis, n (%) 24 (4.3)
Enterococcus spp. n (%) 11 (2.0)
Unclassified Gram-positive bacteria, n (%) 5 (0.9)
Streptococcus spp. n (%) 3 (0.5)
Streptococcus pnemoniae, n (%) 1 (0.2)
Total, n (%) 73 (13.1)
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Kraker et al., 2011; Resch, Wilke, Fink, 2009; Mulvey, 
Simor, 2009). Hence, the detection of antimicrobial 
resistance patterns in every hospital plays an important 
role in the management of infections.
Hospital-acquired infections are life-threatening 
conditions that involve patients, especially those admitted 
to ICUs. Respiratory pathogens are responsible for about 
one-third of ICU infections (Garner et al., 1998; Flanders, 
Collard, Saint, 2006). In the present study, the most 
common site of infection was the respiratory tract (51.7 
%); this result is in agreement with other studies conducted 
indifferent countries including Turkey (38.8 %) (Gunseren 
et al., 1999), India (29.7%) (Orrett, 2002), Oman (65%) 
(Al-Lawati, Crouch, Elhag, 2000), Italy (91%) (Bassetti et 
TABLE II - Susceptibility rates of the most common Gram-positive cocci isolated from the ICUs
Organisms




Disc n 29 24 11 3 1 5
AMP S 2 _ _ _ 1 _
R 7 1 _ _ _ _
IPM S _ _ _ _ 1 _
R 3 1 _ _ _ _
AMK S 2 1 _ _ _ _
R _ 1 _ _ _ _
GEN S 3 1 1 1 1 _
R 10 4 _ 1 _ _
CHL S 13 1 1 1 _ _
R 1 _ 1 _ _ _
SXT S 7 5 _ 1 1 _
R 8 1 3 2 _ _
NIT S 1 3 2 _ _ _
R _ _ _ _ _ _
CIP S 2 1 _ 1 _ _
R 8 4 1 _ _ _
CLI S 4 1 1 _ _ _
R 9 4 _ 1 _ _
VAN S 23 9 1 2 1 _
R _ 1 1 _ _ _
RIF S 1 _ _ _ _ _
R 2 _ _ _ _ _
OXA S 1 _ _ _ _ _
R 15 6 _ 1 1 _
PEN S _ _ _ _ _ _
R 1 2 _ 2 1 _
CEF S _ _ _ _ _ _
R 1 _ _ _ _ _
R= Resistant, S= Sensitive, – = Not measured or not reported, AMP= Ampicillin, IPM= Imipenem, AMK= Amikacin, GEN= 
Gentamicin, CHL= Chloramphenicol, SXT= trimethoprim-sulfamethoxazole, NIT= Nitrofurantoin, CIP= Ciprofloxacin, CLI= 
Clindamycin, VAN= Vancomycin, RIF= Rifampine, A= Oxacillin, PEN= Penicillin, CEF= Cefazolin.
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TABLE III - Susceptibility rates of Gram-negative bacilli isolated from the ICU
Organisms




Disc n 42 93 5 31 282 5 25
CAZ S 3 8 _ 1 10 _ 2
R b 6 12 1 11 55 _ 4
AMP S 1 _ _ _ 4 _ 1
R 10 19 1 15 49 1 4
CTX S 4 4 _ _ 5 _ 1
R 8 23 2 12 41 2 10
IPM S 6 2 _ _ 12 _ _
R 7 10 1 4 61 1 1
AMK S 20 66 3 20 111 3 11
R 12 9 1 8 61 1 2
GEN S 10 29 1 8 62 1 9
R 16 25 1 8 84 1 _
CHL S 1 16 2 _ 24 _ 1
R 14 11 1 12 78 2 7
SXT S 7 12 _ 1 20 _ 1
R 17 47 2 18 109 3 9
NIT S _ 33 1 _ 16 _ _
R 7 6 _ 2 25 1 2
CIP S 13 23 _ 3 47 1 2
R 10 30 1 13 89 3 _
CLI S _ _ _ _ _ _ _
R _ 2 _ 3 3 1 2
CET S 3 1 _ 1 8 _ 1
R 6 12 1 6 79 _ _
CEZ S 3 6 _ _ 9 _ 1
R 10 11 1 4 49 _ 4
RIF S 1 _ 1 3 26 2 2
R 3 11 _ _ 15 _ 2
OXA S _ _ _ _ 1 _ _
R 9 11 1 6 53 1 1
PEN S _ _ _ _ _ _ _
R _ _ _ _ _ _ _
PIP S _ _ _ _ _ _ _
R _ _ _ _ _ _ _
R= Resistant, S= Sensitive, – = Not measured or not reported, AMK= Amikacin, GEN= Gentamicin, SXT= trimethoprim-
sulfamethoxazole, CIP= Ciprofloxacin, CHL= Chloramphenicol, CET= Ceftriaxone, CTX= Cefotaxime, CAZ= Ceftazidime, AMP= 
Ampicillin, IPM= Imipenem, OXA= Oxacillin, CEZ= Ceftizoxime, NIT= Nitrofurantoin, VAN= Vancomycin, CLI= Clindamycin, 
PEN= Penicillin, PIP= piperacillin.
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al., 2012), the United States (54.4%) (Streit et al., 2004), 
and a separate report from Iran (70.6%) (Mohammadtaheri 
et al., 2010). 
The SENTRY Antimicrobial Surveillance Program 
which included 25 ICUs in Europe (1997-1998) and 
North America (2001) reported S. aureusas the most 
common pathogen in developed countries followed 
by P. aeruginosa and E. coli (Streit et al., 2004; Fluit 
et al., 2001). However, this pattern in developing 
countries such as Brazil (Mendes et al., 2005), Turkey 
(Kucukates, 2005), Iran (Mohammadtaheri et al., 2010), 
and other Middle Eastern countries were documented 
as Pseudomonas and Acinetobacter (Aly, Al-Mousa, 
Al Asar, 2008; Bayram, Balci, 2006). In the present 
study, Enterobacter aerogenes followed by E. coli and 
P. aeruginosa were the organisms most frequently 
recovered from ICUs. In a Serbian report, Enterobacter 
strains were the bacteria most commonly isolated from 
ICUs (Djordjevic et al., 2012).
In the current study, Escherichia coli (36.2%) 
and Enterobacter aerogenes (52.7%) were the isolates 
most commonly found in urinary and respiratory tracts. 
These findings are in agreement with those of the study 
conducted by Streit et al. in North America (Streit et al., 
2004). However, in a report from Oman, Escherichia coli 
and Pseudomonas aeruginosa were the pathogens most 
commonly found in the urinary and respiratory tracts of 
ICU patients (Al-Lawati, Crouch, Elhag, 2000). Whereas, 
Klebsiella and Pseudomonas were the microorganisms 
most commonly found in the urine of patients admitted to 
the ICU of Imam Khomeini Hospital in Tehran (Hadadi 
et al., 2008).
In the current study, 86.2% of microorganisms 
isolated from urine were gram-negative bacteria. This 
finding is in line with a 2003 NNIS study that showed the 
highest rates of gram-negative infections to be in urine 
(Gaynes, Edwards, 2005).
The most common gram-positive organisms 
recovered from the ICUs in this study were S. aureus 
followed by S. epidermidis. This result is in agreement 
with the findings of Mohammadtaheri et al. (2010) and 
Khalili et al. (2012) in their studies conducted in ICU and 
infectious ward settings in Iran. ().
In the present study, MRSA made up 87.5% of all 
S.aureus isolates. This rate is higher than those reported 
from Canada (CAN-ICU study) (22.3%) (Zhanel et al., 
TABLE IV - Overall susceptibility rates of the microorganisms isolated from the ICUs
Used discs n (%) Sensitive Resistant
N % N %
AMK 333 (59.8) 238 71.5 95 28.5
GEN 278 (50.0) 128 46.0 150 54.0
SXT 275 (49.4) 55 20.0 220 80.0
CIP 259 (46.5) 93 35.0 166 65.0
CHL 188 (33.8) 60 32.0 128 68.0
CET 123 (22.1) 15 12.2 108 87.8
CTX 117 (21.0) 15 12.8 102 87.2
CAZ 117 (21.0) 24 20.5 93 79.5
AMP 116 (19.8) 9 7.8 107 92.2
IPM 111 (20.0) 21 19.0 90 81.0
OXA 107 (19.3) 2 1.8 105 98.2
CEZ 100 (18.0) 19 19.0 81 81.0
NIT 99 (17.8) 56 56.5 43 43.5
VAN 39 (7.1) 36 92.3 3 7.7
CLI 31 (5.6) 6 19.4 25 80.6
PEN 6 (1.1) - - 6 100
PIP 1 (0.2) - - 1 100
AMK= Amikacin, GEN= Gentamicin, SXT= trimethoprim-sulfamethoxazole, CIP= Ciprofloxacin, CHL= Chloramphenicol, CET= 
Ceftriaxone, CTX= Cefotaxime, CAZ= Ceftazidime, AMP= Ampicillin, IPM= Imipenem, OXA= Oxacillin, CEZ= Ceftizoxime, 
NIT= Nitrofurantoin, VAN= Vancomycin, CLI= Clindamycin, PEN= Penicillin, PIP= piperacillin.
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2008), Europe (39%) (Fridkin, 2001), and the USA (55%) 
(Styers et al., 2006), but it is comparable with the report 
from Turkey (82%) (Bayram, Balci, 2006). Also, the rate 
of MRSA in the current study is lower than that report 
separately from Iran (96.2%) (Mohammadtaheri et al., 
2010).
All MRSA isolates in the current study were 
susceptible to vancomycin; this is in line with the report 
from Iran and the CAN-ICU study (Mohammadtaheri et 
al., 2010; Khalili et al., 2012; Zhanel et al., 2008). The 
other active agent against MRSA was trimethoprim-
sulfamethoxazole (46.7%); this result is similar to that 
of Mohammadtaheri et al. (51.9%) (Mohammadtaheriet 
al., 2010), but it is far from that of the CAN-ICU study 
(11.7%) (Zhanel et al., 2008).
Currently, MRSA is an emerging problem associated 
with a higher rate of mortality and increased durations of 
hospitalization and healthcare costs (Giskeet al., 2008; 
De Kraker et al., 2011).This higher rate of MRSA should 
raise the concerns of health authorities and lead to a larger 
battle against the propagation of infections.
In the present investigation, the resistance rate of 
pathogens to imipenem was documented in more than 
80% of isolates; this rate is higher than those of Belgium 
(13%) (Glupczynski et al., 2001), Poland (8%) (Patzer, 
Dzierzanowska,Turner, 2002), and Turkey (20.8%) 
(Kucukates, 2005).
Recent data from Iran revealed that the resistance 
of microorganisms to imipenem has increased. The 
susceptibility rates of pathogens to imipenem in earlier 
studies from Iran were about 98% and 87.5% in 2006 
and 2008, respectively (Vessal et al., 2006; Hadadi et al., 
2008). In 2010, however, the authors of the current study 
reported the decline of these rates to 2-37% and 19%, 
respectively (Mohammadtaheri et al., 2010). Accordingly, 
it may be concluded that the appearance of pathogens 
resistant to imipenem is increasing in Iran with the passing 
of time and consumption of the drug. 
Antimicrobial resistance to ciprofloxacin was 
documented in 65% of cases. This rate in reports from 
Iran, Turkey, and Belgium was 76%, 29%, and 21%, 
respectively (Kucukates, 2005; Hadadi et al., 2008; 
Glupczynski et al., 2001).
The overall resistance rate of antimicrobials was 
higher in the current study than in other reports (Gunseren 
et al., 1999; Mendes et al., 2005; Styers et al., 2006; 
Patzer, Dzierzanowska, Turner, 2002; Gonlugur et al., 
2004; Karlowsky et al., 2003). Moreover, the resistance 
rate to cephalosporins (79.5%-87.8%) was comparable to 
that in Iran (Hadadiet al., 2008), but higher than reported 
in foreign studies (Gunseren et al., 1999; Al-Lawati, 
Crouch, Elhag, 2000; Glupczynski et al., 2001; Patzer, 
Dzierzanowska,Turner, 2002; Gonlugur et al., 2004; 
Karlowsky et al., 2003; Meric et al., 2005).
Cur r en t  r e su l t s  a l so  showed  tha t  25 .8% 
of Acinetobacter, 20% of Klebsiella, and 16.6% of 
Pseudomonas were an MDR gram-negative pathogen. 
In one study from Turkey from 2000 to 2002, 45.4% of 
Acinetobacters and 37.7% of P. aeruginosa isolates were 
MDR (Yaman et al., 2004). In another study conducted in 
Iran, 80% of Acinetobacter and 59% of Klebsiella isolates 
were MDR (Hadadi et al., 2008). In the Karlowsky et al. 
(2003) study, among Acinetobacter isolates, the MDR rate 
was 11.6-24.2%. 
MDR gram-negative bacilli-related infections have 
become a major, rising problem (Thomson, Bonomo, 
2005). Despite the growth of MDR strains, very few 
antimicrobials have been developed to combat these 
infections (Rubinstein, Vaughan, 2005). The growing 
body of evidence also proves the development of resistant 
gram-negative infections without adequate therapeutic 
options (Falagas et al., 2005). Moreover, MDR gram-
negative infections are associated with increased mortality 
rates, extended durations of hospitalization, and higher 
healthcare costs (Bergman et al., 2006).
At the end, the results of the present study showed a 
higher rate of antimicrobial resistance patterns in the ICUs of 
the largest referral tertiary teaching hospital in northwestern 
Iran. The irrational use of antibiotics reported in this study 
may partially justify these results. Therefore, detecting 
and managing bacterial resistance should be given more 
attention by clinicians as an important part of any infection 
control program. Additionally, the development of antibiotic 
stewardship programs in hospitals, encouragement of 
rational antibiotic use, and national and local antibacterial 
surveillances and control programs are recommended to 
reduce the development of resistant strains and encourage 
the successful management of infections.
This study has some limitations. Because of its 
retrospective design, access to clinicians and a medical 
menu was not possible. Therefore, a clinical judgment 
about the administration of antibiotics in some cases was 
not applicable. 
CONCLUSION
This study showed a higher rate of bacterial 
resistance in the ICUs of a tertiary teaching hospital in 
Iran. Due to the emergence of resistant microorganisms 
in ICUs and considering the critical condition of patients 
in such a setting, more surveillance and control of the use 
of antibiotics is needed to combat infections.
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